$18.17
1.51%
Nasdaq, Oct 10, 10:00 pm CET
ISIN
IL0011316309
Symbol
MDWD

MediWound Ltd. Stock price

$18.17
-0.28 1.52% 1M
+3.12 20.73% 6M
+0.37 2.08% YTD
+1.42 8.48% 1Y
+8.93 96.65% 3Y
-7.38 28.88% 5Y
-34.68 65.62% 10Y
-102.72 84.97% 20Y
Nasdaq, Closing price Fri, Oct 10 2025
+0.27 1.51%
ISIN
IL0011316309
Symbol
MDWD
Industry

Key metrics

Basic
Market capitalization
$233.0m
Enterprise Value
$208.6m
Net debt
positive
Cash
$32.4m
Shares outstanding
10.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
11.7 | 9.5
EV/Sales
10.5 | 8.5
EV/FCF
negative
P/B
11.6
Financial Health
Equity Ratio
42.4%
Return on Equity
-97.0%
ROCE
-58.3%
ROIC
-404.1%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$19.9m | $24.5m
EBITDA
$-20.6m | $-32.2m
EBIT
$-22.1m | $-23.9m
Net Income
$-28.0m | $-30.5m
Free Cash Flow
$-19.3m
Growth (TTM | estimate)
Revenue
-1.4% | 21.4%
EBITDA
-50.3% | -73.7%
EBIT
-46.2% | -23.3%
Net Income
-39.9% | -1.1%
Free Cash Flow
13.5%
Margin (TTM | estimate)
Gross
18.4%
EBITDA
-103.8% | -131.3%
EBIT
-111.4%
Net
-140.8% | -124.4%
Free Cash Flow
-97.0%
More
EPS
$-2.6
FCF per Share
$-1.8
Short interest
8.6%
Employees
111
Rev per Employee
$180.0k
Show more

Is MediWound Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,999 stocks worldwide.

MediWound Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a MediWound Ltd. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a MediWound Ltd. forecast:

Buy
92%
Hold
8%

Financial data from MediWound Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
20 20
1% 1%
100%
- Direct Costs 16 16
7% 7%
82%
3.66 3.66
37% 37%
18%
- Selling and Administrative Expenses 14 14
23% 23%
70%
- Research and Development Expense 12 12
77% 77%
60%
-21 -21
50% 50%
-104%
- Depreciation and Amortization 1.51 1.51
7% 7%
8%
EBIT (Operating Income) EBIT -22 -22
46% 46%
-111%
Net Profit -28 -28
40% 40%
-141%

In millions USD.

Don't miss a Thing! We will send you all news about MediWound Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediWound Ltd. Stock News

Neutral
GlobeNewsWire
14 days ago
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
Neutral
GlobeNewsWire
18 days ago
MediWound Expands Global Reach with Marketing Approval of NexoBrid ® in Australia
Neutral
GlobeNewsWire
about one month ago
MediWound's NexoBrid ® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin,...
More MediWound Ltd. News

Company Profile

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Head office Israel
CEO Ofer Gonen
Employees 111
Founded 2000
Website www.mediwound.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today